These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. RGD peptide functionalized and reconstituted high-density lipoprotein nanoparticles as a versatile and multimodal tumor targeting molecular imaging probe. Chen W; Jarzyna PA; van Tilborg GA; Nguyen VA; Cormode DP; Klink A; Griffioen AW; Randolph GJ; Fisher EA; Mulder WJ; Fayad ZA FASEB J; 2010 Jun; 24(6):1689-99. PubMed ID: 20075195 [TBL] [Abstract][Full Text] [Related]
23. RGD binding to integrin alphavbeta3 affects cell motility and adhesion in primary human breast cancer cultures. Georgoulis A; Havaki S; Drosos Y; Goutas N; Vlachodimitropoulos D; Aleporou-Marinou V; Kittas C; Marinos E; Kouloukoussa M Ultrastruct Pathol; 2012 Dec; 36(6):387-99. PubMed ID: 23181508 [TBL] [Abstract][Full Text] [Related]
24. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. Mulder WJ; Strijkers GJ; Habets JW; Bleeker EJ; van der Schaft DW; Storm G; Koning GA; Griffioen AW; Nicolay K FASEB J; 2005 Dec; 19(14):2008-10. PubMed ID: 16204353 [TBL] [Abstract][Full Text] [Related]
25. Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. Dijkgraaf I; Liu S; Kruijtzer JA; Soede AC; Oyen WJ; Liskamp RM; Corstens FH; Boerman OC Nucl Med Biol; 2007 Jan; 34(1):29-35. PubMed ID: 17210459 [TBL] [Abstract][Full Text] [Related]
26. RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Danhier F; Le Breton A; Préat V Mol Pharm; 2012 Nov; 9(11):2961-73. PubMed ID: 22967287 [TBL] [Abstract][Full Text] [Related]
27. Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Janssen M; Oyen WJ; Massuger LF; Frielink C; Dijkgraaf I; Edwards DS; Radjopadhye M; Corstens FH; Boerman OC Cancer Biother Radiopharm; 2002 Dec; 17(6):641-6. PubMed ID: 12537667 [TBL] [Abstract][Full Text] [Related]
28. Conjugates of a novel 7-substituted camptothecin with RGD-peptides as α(v)β₃ integrin ligands: An approach to tumor-targeted therapy. Dal Pozzo A; Esposito E; Ni M; Muzi L; Pisano C; Bucci F; Vesci L; Castorina M; Penco S Bioconjug Chem; 2010 Nov; 21(11):1956-67. PubMed ID: 20949910 [TBL] [Abstract][Full Text] [Related]
29. Self-assembled nanoparticles based on glycol chitosan bearing 5beta-cholanic acid for RGD peptide delivery. Park JH; Kwon S; Nam JO; Park RW; Chung H; Seo SB; Kim IS; Kwon IC; Jeong SY J Control Release; 2004 Mar; 95(3):579-88. PubMed ID: 15023468 [TBL] [Abstract][Full Text] [Related]
30. [Vascular endothelial cells targeted Tyr-RGD-PEG-PEI nano-drug synthesis and its biological activity]. Gao Y; He SL; Zhong GR; Cai HP; Li Q Yao Xue Xue Bao; 2009 Sep; 44(9):1034-9. PubMed ID: 20055181 [TBL] [Abstract][Full Text] [Related]
31. The C-terminus of alpha2-antiplasmin interacts with endothelial cells. Thomas L; Moore NR; Miller S; Booth NA Br J Haematol; 2007 Feb; 136(3):472-9. PubMed ID: 17176267 [TBL] [Abstract][Full Text] [Related]
32. Specific targeting of tumor angiogenesis by RGD-conjugated ultrasmall superparamagnetic iron oxide particles using a clinical 1.5-T magnetic resonance scanner. Zhang C; Jugold M; Woenne EC; Lammers T; Morgenstern B; Mueller MM; Zentgraf H; Bock M; Eisenhut M; Semmler W; Kiessling F Cancer Res; 2007 Feb; 67(4):1555-62. PubMed ID: 17308094 [TBL] [Abstract][Full Text] [Related]
33. A novel solid lipid nanoparticle formulation for active targeting to tumor α(v) β(3) integrin receptors reveals cyclic RGD as a double-edged sword. Shuhendler AJ; Prasad P; Leung M; Rauth AM; Dacosta RS; Wu XY Adv Healthc Mater; 2012 Sep; 1(5):600-8. PubMed ID: 23184795 [TBL] [Abstract][Full Text] [Related]
34. Multivalent cyclic RGD ligands: influence of linker lengths on receptor binding. Kubas H; Schäfer M; Bauder-Wüst U; Eder M; Oltmanns D; Haberkorn U; Mier W; Eisenhut M Nucl Med Biol; 2010 Nov; 37(8):885-91. PubMed ID: 21055618 [TBL] [Abstract][Full Text] [Related]
35. Anti-angiogenesis activities of novel peptide complexes: mitochondria-disruptive 9mer peptides conjugated with the integrin alpha V beta 3-homing cyclic RGD motif. Iwasaki T; Yamakawa M; Asaoka A; Kawano T; Ishibashi J Biosci Biotechnol Biochem; 2012; 76(11):2044-8. PubMed ID: 23132564 [TBL] [Abstract][Full Text] [Related]
37. Modification of the C16Y peptide on nanoparticles is an effective approach to target endothelial and cancer cells via the integrin receptor. Hamano N; Negishi Y; Fujisawa A; Manandhar M; Sato H; Katagiri F; Nomizu M; Aramaki Y Int J Pharm; 2012 May; 428(1-2):114-7. PubMed ID: 22421321 [TBL] [Abstract][Full Text] [Related]
38. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Chen X; Conti PS; Moats RA Cancer Res; 2004 Nov; 64(21):8009-14. PubMed ID: 15520209 [TBL] [Abstract][Full Text] [Related]
39. Preparation and characterization of 99mTc(CO)3-BPy-RGD complex as alphav beta3 integrin receptor-targeted imaging agent. Zhang X; Chen X Appl Radiat Isot; 2007 Jan; 65(1):70-8. PubMed ID: 17011200 [TBL] [Abstract][Full Text] [Related]
40. NC-100717: a versatile RGD peptide scaffold for angiogenesis imaging. Indrevoll B; Kindberg GM; Solbakken M; Bjurgert E; Johansen JH; Karlsen H; Mendizabal M; Cuthbertson A Bioorg Med Chem Lett; 2006 Dec; 16(24):6190-3. PubMed ID: 17000103 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]